Monoclonal Antibodies Antibodies produced in the laboratory by specialized cells called hybridomas. The important features of these Antibodies include their specificity of binding to a single antigen (protein), the ability to

in 1991 as Director of Monoclonal Antibodies and led the project to develop BTI-322 ® , an anti-CD2 Monoclonal antibody, the humanized version of which is currently in clinical trials for treatment of psoriasis. In 1995, she was promoted